Comparative Pharmacokinetic and Pharmacodynamic Effects of Delta-8 and Delta-9 THC

Summary

The current study will investigate the subjective, physiological, and cognitive performance effects of inhaled and orally ingested Delta-8 tetrahydrocannabinol (THC) in comparison to both placebo and Delta-9 THC. The purpose of this study is to assess the effects of Delta-8 THC as compared to placebo and Delta-9 THC. Oral fluid, urine, blood, and hair specimens will be collected from participants.

Conditions

• Behavioral Pharmacology of Cannabis

Interventions

DRUG

Oral Delta-8-THC Cannabis

Delta-8-THC cannabis will be orally self-administered by study participants

DRUG

Oral Delta-9-THC Cannabis

Delta-9-THC cannabis will be orally self-administered by study participants

DRUG

Oral Placebo

Placebo will be orally self-administered by study participants

DRUG

Vaporized Delta-8-THC Cannabis

Delta-8-THC cannabis will be self-administered by study participants using a vaporizer

DRUG

Vaporized Delta-9-THC Cannabis

Delta-9-THC cannabis will be self-administered by study participants using a vaporizer

DRUG

Vaporized Placebo

Placebo will be self-administered by study participants using a vaporizer

Sponsors & Collaborators

• Substance Abuse and Mental Health Services Administration (SAMHSA)

  collaborator FED

• Johns Hopkins University

  lead OTHER

Principal Investigators

• Ryan Vandrey, PhD · Johns Hopkins University

Study Design

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

DOUBLE

Model

CROSSOVER

Eligibility

Min Age

18 Years

Max Age

45 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2022-05-23

Primary Completion

2024-08-08

Completion

2024-10-02

FDA Drug

Yes

Countries

• United States

Study Locations